In the current study, the authors also identified the transcription factor SOX9 (SRY-Box 9), a high-mobility group domain-containing DNA-binding effector, as a putative regulator of cardiac fibrosis during ischemic injury. In humans, inactivating mutations in the SOX9 gene results in chondrogenesis, hair growth, sex-specification disorders, and tumor formation in numerous organs. [6] [7] [8] Moreover, SOX9 was originally described as a regulator of cell stemness, tissue regeneration, and cell fate decisions, and a potent regulator of transcription for extracellular matrix genes. 6, 9 SOX9 was also already known to contribute to the fibrotic response in the liver and kidney. 6 In the heart, SOX9 was shown to be required for normal valve and septum development through a mechanism involving epithelial-mesenchymal transition, endocardial cushions precursor cells expansion, and extracellular matrix organization. 10, 11 Indeed, fibroblast-specific deletion of Sox9 in the mouse with a Col2a1 promoter-driven Cre recombinase resulted in defective extracellular matrix production in the valves. 11 In the current study, Lacraz et al 2 demonstrated induction of SOX9 expression in the adult mouse heart 14 days after ischemia/reperfusion injury
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The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. and in human ischemic heart disease samples. They also presented evidence that SOX9 colocalized with the fibroblast marker genes vimentin, periostin, and collagen type I. In the mouse, tamoxifen-inducible heterozygous Sox9-loxP deletion mediated by a ubiquitous Cre allele contained within the Rosa26 locus reduced the fibrotic response and gene program 14 days after ischemic injury. In the future, it will be important to investigate SOX9 function in a fibroblast-specific manner using an appropriate Cre recombinase-expressing mouse line and to also target both Sox9 alleles to achieve an even greater loss-of-function effect. However, Lincoln et al 11 showed that homozygous Sox9-loxP-targeted mice were embryonic lethal when crossed with either a Col2a1-Cre or Tie-2-Cre line, likely explaining why Lacraz et al 2 only used a heterozygous Sox9-loxP strategy when crossed with their ubiquitous Rosa26-Cre line. Thus, future studies need to be fibroblast-specific as well as utilize an inducible strategy to bypass embryonic lethality associated with homozygous conditional targeting of Sox9 in the mouse.
Finally, Lacraz et al 2 proposed a list of transcriptionally active Col1a2 coexpressed genes that displayed SOX9 occupancy, indicating that SOX9 could regulate a specific fibrotic gene program in the heart after ischemia. Overall, the study by Lacraz et al 2 is timely and important because it opens new technical approaches for the field to adopt and highlights novel molecular signature genes regulating cardiac fibrosis for further mechanistic assessment. The study by Lacraz et al 2 also raises a number of fascinating future questions related to the role of SOX9 as a nodal transcription factor underlying the fibrotic response in the adult heart. The nature of the upstream signals leading to SOX9 induction would also be important to characterize, such as the potential involvement of transforming growth factor-β and its associated signaling effectors. Interestingly, if SOX9 is specifically induced 14 days after ischemia-reperfusion in the adult heart as suggested, then such timing suggests that this factor could regulate a unique subset of fibrosis genes that might help with scar stability after acute ischemic injury, rather than regulating fibroblast proliferation or earlier events in their activation. Further interrogation and lineage tracing of SOX9-expressing fibroblasts might also suggest a potential substage in the differentiation of these cells that is unique to SOX9 expression, which could have therapeutic ramifications for diseases in which cardiac fibrosis is prominent. 
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